Jardiance Duo Indications/Uses

Glycaemic control: Adults: JARDIANCE DUO is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: when treatment with both empagliflozin and metformin is appropriate; inadequately controlled with metformin or empagliflozin alone; inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin (see Pharmacology: Clinical Trials under Actions); already treated with empagliflozin and metformin co-administered as separate tablets.
Pediatric population: JARDIANCE DUO is indicated as an adjunct to diet and exercise to improve glycaemic control in children aged 10 years and above with type 2 diabetes mellitus: when treatment with both empagliflozin and metformin is appropriate; inadequately controlled with metformin alone or in combination with insulin (see Pharmacology: Clinical Trials under Actions); already treated with empagliflozin and metformin co-administered as separate tablets.
Prevention of cardiovascular events: Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. However, the effectiveness of Jardiance Duo on reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease has not been established.